Concurrent Use of Lorazepam and Alprazolam: Clinical Recommendation

Primary Safety Concerns

The CDC explicitly warns against concurrent benzodiazepine use with other CNS depressants due to the compounded risk of respiratory depression and fatal overdose 1
Both lorazepam and alprazolam depress the central nervous system through the same GABA-A receptor mechanism, creating additive—not synergistic—sedative effects 1
The sedative effects are dose-dependent and cumulative across different benzodiazepines 2

Using two benzodiazepines simultaneously increases total daily benzodiazepine exposure, accelerating the development of physiologic dependence 3, 4
Withdrawal from multiple benzodiazepines is more complex and dangerous than tapering a single agent 3

Cognitive Behavioral Therapy (CBT) is the preferred first-line treatment for anxiety and panic disorders, not benzodiazepines 4
The WHO explicitly recommends CBT-based psychological interventions over benzodiazepines for individuals with panic attacks 4
Benzodiazepines should be reserved for patients who have failed or cannot access CBT 4
If breakthrough anxiety occurs despite scheduled benzodiazepine dosing, consider adding evidence-based alternatives rather than a second benzodiazepine 1
Antidepressants (SSRIs/SNRIs) for long-term anxiety management 1
Gabapentin, trazodone, or mirtazapine as adjuncts for specific symptoms 3
Hydroxyzine or buspirone for additional anxiolytic effect without benzodiazepine-related risks 1

Do not abruptly discontinue either medication due to serious withdrawal risks including seizures, delirium tremens, and rarely death 1, 3
Consolidate to a single benzodiazepine using a gradual cross-taper strategy 3
Generally safer to taper the shorter-acting agent (alprazolam) first while maintaining the longer-acting agent (lorazepam) 1
Alprazolam taper: Reduce by 0.25 mg every 1-2 weeks, or 10% of current dose for slower taper 3
Lorazepam taper: Reduce by 25% every 1-2 weeks once alprazolam is discontinued 1
Liberally use clonidine, gabapentin, trazodone, or mirtazapine to manage withdrawal symptoms 3
CBT significantly increases tapering success rates and should be offered concurrently 1, 3

Never prescribe two benzodiazepines simultaneously as initial therapy—this represents polypharmacy without evidence of benefit, as warned by the CDC 1
Avoid the misconception that "PRN" dosing of a second benzodiazepine is safer—-the risks of concurrent use apply regardless of scheduling 1
Do not assume alprazolam's shorter half-life makes it safer for PRN use—its rapid onset actually increases abuse potential and interdose rebound anxiety 4